Hospital
Cullman Regional Medical Center, INC
Cullman Regional Medical Center, INC was paid $7.50M by Medicaid between Jan 2018 and Dec 2024, across 116 billing codes. Its largest line is 99284, emergency room visit (serious) — 29% of everything it billed.
33Billing provider infoCULLMAN REGIONAL MEDICAL CENTER, INC
CULLMAN, AL 35058
CULLMAN, AL 35058
33aNPI1114919339assigned 08/16/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$7.50M
24GClaims272,753
24DCodes billed116
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Alabama
Rank by total paid#6 of 77
Median peer was paid$1.13M
This provider vs. median6.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 35,114 | $576K | |
| 2019 | 36,497 | $632K | |
| 2020 | 28,181 | $554K | |
| 2021 | 38,298 | $1.10M | |
| 2022 | 41,367 | $1.23M | |
| 2023 | 54,445 | $2.06M | |
| 2024incomplete | 38,851 | $1.35M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 29% | 34,190 | 29,731 | $2.21M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 23% | 7,880 | 7,153 | $1.70M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 29,324 | 26,247 | $1.12M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.2% | 3,325 | 2,864 | $242K |
| 80053 | Comprehensive metabolic panel | 3.1% | 23,533 | 20,048 | $233K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.7% | 1,281 | 1,131 | $201K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.7% | 2,306 | 2,103 | $199K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.6% | 24,971 | 21,219 | $195K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 12,578 | 10,471 | $125K |
| 87081 | 1.6% | 13,070 | 12,138 | $122K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.5% | 10,536 | 9,150 | $109K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.4% | 4,956 | 4,369 | $108K |
104 more codes
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.3% | 950 | $98K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.3% | 6,204 | $94K |
| 71045 | Radiologic examination, chest; single view | <1% | 13,229 | $66K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 926 | $60K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,145 | $53K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 361 | $47K |
| 87430 | <1% | 2,521 | $42K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,954 | $39K |
| 84484 | <1% | 5,126 | $38K | |
| 83690 | <1% | 5,469 | $36K | |
| 97597 | <1% | 1,385 | $33K | |
| 81025 | <1% | 8,593 | $29K | |
| 81003 | <1% | 11,509 | $27K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 679 | $26K |
| 81001 | <1% | 5,093 | $20K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 453 | $13K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 669 | $13K |
| 83605 | <1% | 1,240 | $12K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 225 | $10K |
| 59025 | Fetal non-stress test | <1% | 2,091 | $9K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 234 | $9K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 17 | $9K |
| 80306 | <1% | 914 | $9K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 108 | $8K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 898 | $8K |
| 83880 | <1% | 272 | $8K | |
| 83735 | <1% | 843 | $6K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 159 | $6K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 388 | $6K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 859 | $5K |
| 85610 | <1% | 1,493 | $5K | |
| 84439 | <1% | 559 | $5K | |
| 87186 | <1% | 425 | $4K | |
| 86592 | <1% | 610 | $4K | |
| 87040 | <1% | 354 | $4K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 74 | $4K |
| 82607 | <1% | 249 | $4K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 114 | $4K |
| 85027 | <1% | 598 | $4K | |
| 0002A | <1% | 121 | $3K | |
| 87077 | <1% | 336 | $3K | |
| 0001A | <1% | 131 | $3K | |
| 87806 | <1% | 107 | $3K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 19 | $3K |
| 82150 | <1% | 468 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,647 | $3K |
| 87807 | <1% | 238 | $3K | |
| 86762 | <1% | 102 | $2K | |
| 86803 | <1% | 105 | $2K | |
| 95811 | <1% | 14 | $2K | |
| 87340 | <1% | 124 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 805 | $2K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 39 | $2K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 235 | $2K |
| 81015 | <1% | 609 | $2K | |
| 86709 | <1% | 91 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,735 | $1K |
| 85730 | <1% | 876 | $1K | |
| 86850 | <1% | 186 | $1K | |
| 86900 | <1% | 365 | $1K | |
| 86901 | <1% | 365 | $1K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 639 | $1K |
| 87070 | <1% | 62 | $794.01 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 82 | $707.93 |
| 80061 | Lipid panel | <1% | 27 | $529.69 |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 14 | $500.30 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 59 | $480.87 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 23 | $413.03 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 12 | $358.82 |
| 82947 | <1% | 59 | $319.28 | |
| 82247 | <1% | 63 | $305.55 | |
| 83655 | <1% | 16 | $266.40 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 557 | $264.48 |
| 84481 | <1% | 16 | $257.55 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 118 | $216.80 |
| 84466 | <1% | 12 | $207.02 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 13 | $205.26 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 152 | $186.98 |
| 72100 | <1% | 16 | $179.37 | |
| 84702 | <1% | 14 | $171.90 | |
| 82746 | <1% | 12 | $159.06 | |
| 82728 | <1% | 12 | $123.31 | |
| 82550 | <1% | 15 | $114.03 | |
| 83540 | <1% | 12 | $85.03 | |
| 85380 | <1% | 13 | $82.95 | |
| 85044 | <1% | 12 | $69.52 | |
| 84436 | <1% | 12 | $53.10 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 25 | $19.28 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 485 | $12.00 |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,333 | $6.24 |
| 82962 | <1% | 114 | $2.85 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,084 | $0.35 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 118 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 133 | $0.00 |
| 96375 | Therapeutic injection; each additional sequential IV push | 0% | 36 | $0.00 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 81 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 43 | $0.00 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 0% | 82 | $0.00 |
| 80320 | 0% | 122 | $0.00 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 0% | 54 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 15 | $0.00 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 0% | 144 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 169 | $0.00 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDONALDSON, NESHA (CFO)
| Provider | Location | Paid |
|---|---|---|
| Health Care Authority of Cullman | Cullman, AL | $1.72M |
| CRMC Medical Group LLC | Cullman, AL | $974K |
| Cullman Regional Medical Group Hospitalists LLC | Cullman, AL | $202K |
| Cullman Regional Medical Center , INC. | Cullman, AL | $117K |
| Cullman Regional Medical Center, INC | Cullman, AL | $41K |
| Cullman Regional Anesthesia Services LLC | Cullman, AL | $18K |
| Cullman Regional Medical Center INC | Cullman, AL | $4K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.